Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Malignant Solid Tumor × etirinotecan pegol × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Small Cell Lung Carcinoma 2 Breast Neoplasms 2 Oligodendroglioma 1 Neoplasms 1 Neoplasm Metastasis 1 Malignant Solid Tumor 1 Glioblastoma 1 Colorectal Neoplasms 1 Carcinoma 1 Astrocytoma 1 Advanced Cancer 1

Interventions

pembrolizumab 3 Ramucirumab 2 etirinotecan pegol 1 cemiplimab 1 Ribavirin 1 Paclitaxel 1 Nivolumab 1 Injections 1 Fluorouracil 1 Docetaxel 1 Decitabine 1 Cisplatin 1 Carboplatin 1 Antibodies, Bispecific 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01457118 2021-07-12

An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies

Nektar Therapeutics

Phase 2 Completed

27 enrolled 18 charts

Other solid neoplasm

Malignant Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡